Side-by-side comparison of AI visibility scores, market position, and capabilities
Ammobia raised $40M in 2024 for its modular electrochemical ammonia synthesis technology that produces green ammonia from air, water, and renewable electricity — without the high-pressure Haber-Bosch process.
Ammobia is developing an electrochemical ammonia synthesis process that produces ammonia at low temperature and pressure using renewable electricity, bypassing the energy-intensive Haber-Bosch process that currently accounts for 1.8% of global CO2 emissions. The company's electrochemical cell directly reduces atmospheric nitrogen and water to ammonia using a proprietary catalyst and membrane architecture, enabling distributed small-scale production near farms or hydrogen hubs.
$40M+ total raised including $26.5M Series A. 2026-27 cattle field trials underway. Backed by Breakthrough Energy Ventures. Only company with a cattle methane vaccine in active trials.
ArkeaBio is developing a vaccine that reduces methane emissions from cattle and sheep by targeting the methanogenic archaea (ancient microorganisms) that produce methane in ruminant digestive systems. The company has raised $40 million+ including a $26.5 million Series A, backed by Breakthrough Energy Ventures and Gates Foundation-aligned capital, and has active cattle field trials underway in 2026-2027 — making it the only company with a livestock methane vaccine at this stage of clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.